The week in health tech, explained in plain English.Get the free newsletter →
November 12, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Finance

UChicago Medicine Shifts Staff to Harder Revenue Cycle Work

UChicago Medicine is automating routine parts of its revenue cycle, including insurance verification and prior authorization, and redeploying staff to more complex work, according to Becker's Hospital Review. Matthew Kennedy, director of patient access and financial clearance, described the approach during a panel at Becker's 11th Annual Health IT + Digital Health Conference.

The idea is straightforward. Software now handles predictable, high-volume tasks that once consumed staff hours. Employees are moved toward cases that require human judgment, such as tricky payer disputes and denials that automation cannot resolve on its own. That reframes automation as a way to reallocate labor rather than simply cut headcount.

The move reflects a broader trend across hospital finance operations. Systems are under margin pressure and struggle to hire and retain skilled revenue cycle workers. By pushing routine work to technology, health systems aim to reduce burnout, keep experienced staff engaged, and improve collections on the hardest claims.

More in Finance

Finance

McLeod Health Operating Income Drops 9.7% as Costs Rise

McLeod Health's operating income fell 9.7% to $137.5 million in fiscal 2026 as expenses grew faster than its 8% revenue increase.

Why it matters: It shows that even revenue-growing health systems are losing margin as costs outpace reimbursement.

Finance

Novartis Lp(a) Drug Lowers Risk Marker but Fails on Outcomes

Novartis's pelacarsen lowered the cardiovascular risk marker Lp(a) but failed to reduce heart attacks or strokes, undermining a major industry strategy.

Why it matters: A failed outcomes trial for a leading Lp(a) drug threatens billions in cardiovascular research built on the assumption that lowering the marker prevents events.

Finance

Novo's Ziltivekimab Flops, But Cardiologists Stay Bullish

Novo Nordisk's ziltivekimab missed in the ZEUS cardiovascular trial, but cardiologists say the anti-inflammatory approach to heart disease remains valid.

Why it matters: Anti-inflammatory therapy is one of the biggest bets in cardiovascular medicine, and how the field reacts to a high-profile failure shapes billions in future R&D.